Trial Design
Rare Disease Clinical Trial
A rare disease clinical trial is a study evaluating a therapy for a condition affecting fewer than 200,000 people in the U.S. (per the Orphan Drug Act) or fewer than 5 in 10,000 in the EU, characterized by small patient populations, geographic dispersion, and reliance on natural history data and external controls.
Rare disease trials face structural challenges: limited eligible patients per site, heterogeneity of disease, lack of validated endpoints, and ethical constraints on placebo. Designs adapt by using single-arm trials with external controls, cross-over designs, n-of-1 trials, and Bayesian borrowing across cohorts.
FDA Orphan Drug Designation, Rare Pediatric Disease Designation, Fast Track, and Breakthrough Therapy provide regulatory incentives. EMA offers parallel orphan designation and PRIME scheme support.
Related terms
External Control Arm
An external control arm is a comparator group constructed from data outside the current clinical trial; historical trial data, registry data, EHR data, or natural-history studies; used to contextualize results from a single-arm trial when randomization is infeasible.
Accelerated Approval
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.
Patient Recruitment Strategy
A patient recruitment strategy is the documented, multi-channel plan a sponsor or CRO uses to identify, engage, screen, and enroll the participants required to meet a clinical trial's enrollment timeline, sample size, and diversity goals.
See how Kitsa applies this in your trials
Kitsa's agentic AI compresses protocol development, site selection, and patient pre-screening from months into weeks.
Request a demo